The rise of Viagra and its impact on the medicinal landscape presents a complex question for shareholders. While the initial sales figures were astounding, the exclusivity has lapsed, leading to a flood of off-brand https://zaynyqad620258.ssnblog.com/40011446/the-blue-pill-and-pharma-a-risky-investment